Research programme: antibacterials - Kosan/Johnson & Johnson

Drug Profile

Research programme: antibacterials - Kosan/Johnson & Johnson

Alternative Names: JNJ 17156581; JNJ 17156815

Latest Information Update: 25 Jun 2007

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development; Kosan Biosciences
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 26 Oct 2005 This programme is still in active development
  • 30 Sep 2003 Data presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2003) have been added to the Bacterial Infections antimicrobial activity and pharmacodynamics sections
  • 14 Jan 2003 This collaboration between Kosan Biosciences, Johnson & Johnson Research & Development and Ortho-McNeil Pharmaceutical has been extended until 28 December 2003
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top